Key result
Outpatient treatment of DVT with once-daily subcutaneous dalteparin was feasible, with an overall serious complication rate of 0.92% and a 34.5% cost reduction.
Why the study?
Does outpatient treatment with once-daily dalteparin maintain safety and reduce costs in patients with symptomatic deep vein thrombosis?
Does outpatient treatment with once-daily dalteparin maintain safety and reduce costs in patients with symptomatic deep vein thrombosis?
Outpatient treatment of deep vein thrombosis with once-daily subcutaneous dalteparin is safe, feasible, and yields significant cost reductions compared to traditional inpatient care.
Answers are grounded in this paper and cite their sources.
Supports outpatient dalteparin consideration for select DVT patients; leaves open need for randomized confirmation of safety and savings.
OBJECTIVES: To test the safety and feasibility of treating deep vein thrombosis (DVT) in an outpatient setting, using the low molecular weight heparin dalteparin, to calculate the potential and actual cost reductions achievable as a result of such a treatment regimen. DESIGN: An open, nonrandomized, multicentre trial. SETTING: Fourteen hospitals in central Sweden. SUBJECTS: Ambulant patients, aged 18 years or older. with symptomatic DVT in the leg, diagnosed using phlebography or ultrasound (Duplex-Doppler). INTERVENTIONS: Dalteparin (Fragmin) at a fixed dose of 200 i.u. kg-1 body weight, was administered once daily subcutaneously for at least 4 consecutive days. Treatment with warfarin was initiated from the first day of dalteparin administration. Outpatient treatment was encouraged whenever possible Financial calculations were performed independently at two hospitals, giving an average cost for all actions. OUTCOME MEASURES: Increasing severity of symptoms (or thromboembolic recurrences during the 3-months follow-up period), pulmonary embolism (PE), bleeding events, and death during the initial phase and follow-up period. RESULTS: Of 434 patients, 35% and 64% were treated in hospital within 24 and 72 h, respectively, and thereafter as outpatients. The overall frequency of serious complications was 0.92% (exact 95% confidence interval, 0.25-2.35%) during the initial phase and one patient suffered a PE and three patients had a recurrent DVT during the follow-up period. A cost reduction of 2705529 Swedish crowns (34.5%) was achieved in this study compared with traditional in-patient treatment. CONCLUSIONS: Dalteparin, administered subcutaneously, once daily, for the initial treatment of DVT yields large cost reductions and is well tolerated and effective in an outpatient setting.
No takes yet. Share an insight, caveat, or question.
Lindmarker et al. (1996) studied Deep vein thrombosis (DVT) (n=434). Dalteparin vs. Traditional in-patient treatment was evaluated on Increasing severity of symptoms, thromboembolic recurrences, pulmonary embolism, bleeding events, and death during the initial phase and follow-up period (95% CI 0.25-2.35). Outpatient treatment of DVT with once-daily subcutaneous dalteparin was feasible, with an overall serious complication rate of 0.92% and a 34.5% cost reduction.
Synapse has enriched 10 related papers. Consider them for comparative context: